Roth Capital Maintains Buy on Charles & Colvard, Raises Price Target to $3.75
Roth Capital analyst Matt Koranda maintains Charles & Colvard (NASDAQ:CTHR) with a Buy and raises the price target from $3.5 to $3.75.
Charles & Colvard Q4 Sales Tops Consensus
Charles & Colvard Ltd (NASDAQ:CTHR) reported fourth-quarter FY21 sales growth of 119.5% year-on-year, to $9.73 million, beating the analyst consensus of…
Charles & Colvard Q4 EPS $0.27 Beats $0.02 Estimate, Sales $9.70M Beat $8.40M Estimate
Charles & Colvard (NASDAQ:CTHR) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.02 by 1250 percent. This is a 775 percent increase over losses of $(0.04) per share from the
Earnings Scheduled For September 2, 2021
Companies Reporting Before The Bell
• Navios Maritime Holdings (NYSE:NM) is projected to report earnings for its second quarter.
Charles & Colvard Says ‘The estimated increase in net sales for fiscal year 2021 is primarily attributed to the continued rise in finished jewelry net sales, which were the highest in Company history.’
Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company specializing in lab created gemstones, today announced preliminary key financial results for
Charles & Colvard Joins Russell Microcap Index Today
Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company specializing in lab created moissanite and lab grown diamonds, announced today the Company's